Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LAB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStandard BioTools grants 500,000 RSUs to Chief Business Officer Sean Mackay
Filed June 3, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
medium
Chief Business Officer Sean Mackay received 500,000 restricted stock units under the 2026 Equity Incentive Plan, effective June 20, 2026. The grant vests 40% in 2027 and 60% in 2028, contingent on continued service.
Item 5.02 verify on EDGAR → -
medium
The two-tranche vesting schedule (200,000 units in year one, 300,000 in year two) creates retention incentives for a key commercial executive through mid-2028.
8-K: Executive Compensation view on EDGAR →
Summary
Standard BioTools disclosed a significant equity compensation award to its Chief Business Officer, Sean Mackay. The 500,000 RSU grant represents a meaningful retention and incentive package for the executive leading the company's commercial operations. The back-loaded vesting structure—with 60% vesting in the second year—suggests the board is prioritizing longer-term retention.
For retail investors, this filing signals the company's commitment to keeping senior commercial leadership in place through 2028. The size of the grant and the executive's role suggest Standard BioTools may be positioning for important business development or sales initiatives over the next two years. Watch for updates on commercial partnerships, product launches, or revenue guidance that might explain the timing and scale of this compensation package.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 29, 2026, the Human Capital Committee of the Board of Directors of Standard BioTools Inc. (the “Company”) approved a grant of 500,000 restricted stock units for Sean Mackay, Chief Business Officer of the Company, under the Company’s 2026 Equity Incentive Plan (the “2026 Plan”), effective as of June 20, 2026 (the “RSU Award”). Subject to Mr. Mackay continuing to provide services to the Company through the applicable vesting dates, 40% of the RSU Award will vest on June 20, 2027, and the remaining 60% of the RSU Award will vest on June 20, 2028.
The company awarded 500,000 restricted stock units to Sean Mackay, its Chief Business Officer, under the 2026 Equity Incentive Plan. The award vests in two tranches: 200,000 units (40%) vest on June 20, 2027, and 300,000 units (60%) vest on June 20, 2028, contingent on continued service. This represents a significant equity compensation grant to a senior executive.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify